Nucleion Therapeutics

Nucleome Therapeutics is an Oxford-based biotechnology company dedicated to decoding the non-coding 'dark matter' of the human genome to discover novel medicines for autoimmune and inflammatory diseases. The company's proprietary Micro Capture-C (MCC) platform combines high-resolution 3D genome mapping with advanced machine learning to identify the causal genes and regulatory elements underlying complex diseases. This platform allows Nucleome to validate first-in-class therapeutic targets with high precision, particularly in lymphocytes and other immune cells. Their lead candidate, NTP464, is a monoclonal antibody agonist designed to restore immune balance by enhancing the activity of regulatory T cells. Spun out from the University of Oxford in 2019, the company has attracted significant investment from premier life science venture capital firms like Pfizer Ventures and M Ventures.